Product Description
Mechanisms of Action: CAR-T, CD22
Novel Mechanism: Yes
Modality: CAR-T (Unknown Type)
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hebei Senlang Biotechnology Inc., Ltd.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Lymphoma, Non-Hodgkin|Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04626726 |
CAR-T for adult B-ALL | P1 |
Unknown status |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia |
2023-05-30 |
17% |
2023-06-02 |
Primary Endpoints|Trial Status |
NCT04626765 |
CAR-T for Childhood B-ALL | P1 |
Unknown status |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia |
2023-03-30 |
42% |
2023-06-02 |
Primary Endpoints|Treatments|Trial Status |
NCT04626739 |
CAR-T for NHL | P1 |
Unknown status |
Lymphoma, Non-Hodgkin |
2023-03-30 |
56% |
2023-04-01 |
Recent News Events
Date |
Type |
Title |
|---|